HMCIB SPAC 3 (226340) - Cash Flow Conversion Efficiency
Based on the latest financial reports, HMCIB SPAC 3 (226340) has a cash flow conversion efficiency ratio of 0.042x as of June 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩2.56 Billion ≈ $1.73 Million USD) by net assets (₩60.89 Billion ≈ $41.26 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of HMCIB SPAC 3 for the company's overall valuation and market capitalisation.
HMCIB SPAC 3 - Cash Flow Conversion Efficiency Trend (2015–2023)
This chart illustrates how HMCIB SPAC 3's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 226340 share price today for real-time trading data and today's change.
HMCIB SPAC 3 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of HMCIB SPAC 3 ranked by their cash flow conversion efficiency. Review 226340 free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
HansBiomed Corporation
KQ:042520
|
0.036x |
|
Starrag Group Holding AG
SW:STGN
|
0.034x |
|
Merafe
JSE:MRF
|
-0.033x |
|
TON Strategy Co
NASDAQ:TONX
|
-0.015x |
|
ECB Bancorp Inc.
NASDAQ:ECBK
|
0.067x |
|
Goldshore Resources Inc
V:GSHR
|
-0.007x |
|
TMC Life Sciences Bhd
KLSE:0101
|
0.010x |
|
Davicom Semiconductor Inc
TW:3094
|
0.005x |
Annual Cash Flow Conversion Efficiency for HMCIB SPAC 3 (2015–2023)
The table below shows the annual cash flow conversion efficiency of HMCIB SPAC 3 from 2015 to 2023. Also see 226340 current and non-current assets for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | ₩39.84 Billion ≈ $27.00 Million |
₩4.61 Billion ≈ $3.13 Million |
0.116x | +183.54% |
| 2022-12-31 | ₩25.63 Billion ≈ $17.37 Million |
₩-3.55 Billion ≈ $-2.41 Million |
-0.139x | -251.58% |
| 2021-12-31 | ₩22.41 Billion ≈ $15.18 Million |
₩2.05 Billion ≈ $1.39 Million |
0.091x | -0.20% |
| 2020-12-31 | ₩32.52 Billion ≈ $22.04 Million |
₩2.98 Billion ≈ $2.02 Million |
0.092x | -68.80% |
| 2019-12-31 | ₩33.96 Billion ≈ $23.01 Million |
₩9.98 Billion ≈ $6.76 Million |
0.294x | +230.09% |
| 2018-12-31 | ₩24.80 Billion ≈ $16.81 Million |
₩-5.60 Billion ≈ $-3.80 Million |
-0.226x | -194.68% |
| 2017-12-31 | ₩12.67 Billion ≈ $8.59 Million |
₩3.02 Billion ≈ $2.05 Million |
0.239x | +1674.08% |
| 2016-12-31 | ₩12.56 Billion ≈ $8.51 Million |
₩168.86 Million ≈ $114.43K |
0.013x | +174.41% |
| 2015-12-31 | ₩12.40 Billion ≈ $8.41 Million |
₩-224.16 Million ≈ $-151.91K |
-0.018x | -- |
About HMCIB SPAC 3
Bonne Co., Ltd. develops and supplies cosmetics in South Korea. The company offers skin care products, including whitening, wrinkle and pimple treatment, stem-cell peptide, and nano peptide products; and sun care products comprising fluids, creams, emulsions, etc. It also provides hair and body care products; makeup products, such as foundation, powder, compact, loose powder, BB cream, eye liner,… Read more